Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coherus BioSciences, Inc. - Common Stock
(NQ:
CHRS
)
1.160
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
66
Open
1.160
Bid (Size)
1.110 (1)
Ask (Size)
1.250 (1)
Prev. Close
1.160
Today's Range
1.160 - 1.160
52wk Range
0.6603 - 2.870
Shares Outstanding
115,213,407
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
January 22, 2025
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Performance
YTD
-17.14%
-17.14%
1 Month
-19.44%
-19.44%
3 Month
+50.14%
+50.14%
6 Month
-25.16%
-25.16%
1 Year
-57.35%
-57.35%
More News
Read More
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
December 18, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 03, 2024
Via
Benzinga
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
December 03, 2024
Via
Benzinga
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
December 03, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
November 27, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
November 07, 2024
Via
Benzinga
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 06, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
October 30, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
August 01, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
June 30, 2024
Via
Talk Markets
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
June 27, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
June 05, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
May 30, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
May 23, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
May 09, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
May 08, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
May 01, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.